Skip to content

Use of safoof darchini in dyspepsia

Preventive effect of Darchini against zoaf e hazm caused by sue mizaj barid

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2019/05/019275
Enrollment
60
Registered
2019-05-23
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K20-K31- Diseases of esophagus, stomach and duodenum

Interventions

Intervention1: Safoof Darchini: powdered form of Cinnamomum in capsule form administered 2 capsule orally two times a day Control Intervention1: wheat flour: filled in capsule and given orally as 2 Ca

Sponsors

National Institute of Unani Medicine
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Should be suffering with at least 4 or more symptoms mentioned below and with the total symptom score of 20 or more based on 7-point Likert scale (a) Post parandial abdominal distension.â?? (b) Upper abdominal painâ?? (c) Eructation (Belching)â?? (d) Bloatingâ?? (e) Early satietyâ?? (f) Nauseaâ?? (g) Vomitingâ?? (h) Regurgitationâ?? (i) Heartburnâ?? (j) Appetiteâ?? (k) Borborygmus

Exclusion criteria

Exclusion criteria: (i) Age less than 18 years or over 65 years (ii) An advanced chronic illness that would impair follow-up or monitoring (iii) Pregnancy or breast feeding (iv) Previous surgery for ulcers (v) Subjects with previous history of gastroesophageal reflux (vi) Subjects with concomitant symptoms of the irritable bowel syndrome (vii) Drug and alcohol abuse (viii) Mental illness or dementia

Design outcomes

Primary

MeasureTime frame
To assess the efficacy and safety of Darchini in Zoafe Hazm And to Prevent Amraze Sue Mizaj Barid Maddi. To assess the effect of Darchini on quality of life.Timepoint: 2 month

Secondary

MeasureTime frame
improvement in 1. Regurgitation 2. Post parandial abdominal distension 3. Nausea and vomiting 4. Borborygmus 5. Eructation (Belching) 6. Heart burn 7. Early satiety 8. Bloating 9. Appetite assessment (Appetite Assessment Tool) 10. Puffiness Timepoint: 2 months

Countries

India

Contacts

Public ContactDr Zarnigar

National Institute of Unani Medicine

zarnigarriaz@rediffmail.com7022669959

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026